UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (1930) 1930
life sciences & biomedicine (1821) 1821
humans (1455) 1455
animals (1111) 1111
male (878) 878
female (666) 666
potassium (664) 664
pharmacology & pharmacy (544) 544
potassium channels (443) 443
cardiovascular system & cardiology (397) 397
middle aged (372) 372
rats (356) 356
cardiac & cardiovascular systems (328) 328
potassium channel blockers - pharmacology (295) 295
aged (289) 289
dose-response relationship, drug (273) 273
adult (267) 267
neurosciences & neurology (248) 248
abridged index medicus (242) 242
hypertension (229) 229
physiology (228) 228
neurosciences (222) 222
risk factors (221) 221
mice (205) 205
potassium channel blockers - adverse effects (195) 195
analysis (193) 193
electrocardiography (186) 186
rodents (186) 186
cardiac arrhythmia (183) 183
patch-clamp techniques (181) 181
blood pressure (176) 176
treatment outcome (174) 174
drug therapy (169) 169
potassium channel blockers - therapeutic use (169) 169
potassium channels - metabolism (168) 168
research (164) 164
patients (161) 161
rats, sprague-dawley (161) 161
heart failure (159) 159
potassium - blood (158) 158
action potentials - drug effects (157) 157
arrhythmia (156) 156
drugs (156) 156
in vitro techniques (154) 154
studies (154) 154
mortality (153) 153
electrophysiology (148) 148
potassium channels - drug effects (147) 147
heart (144) 144
time factors (142) 142
care and treatment (136) 136
potassium - metabolism (136) 136
calcium (134) 134
pharmacology (134) 134
potassium channel blockers (133) 133
ion channels (132) 132
medicine (130) 130
research article (127) 127
disease models, animal (126) 126
erg1 potassium channel (126) 126
clinical neurology (125) 125
peripheral vascular disease (125) 125
health aspects (123) 123
physiological aspects (120) 120
proteins (120) 120
cardiology (117) 117
medicine & public health (117) 117
blood pressure - drug effects (116) 116
long qt syndrome - chemically induced (116) 116
toxicology (116) 116
ether-a-go-go potassium channels - antagonists & inhibitors (115) 115
hypertension - drug therapy (115) 115
biochemistry & molecular biology (114) 114
rats, wistar (113) 113
cell biology (112) 112
diabetes (110) 110
anti-arrhythmia agents - pharmacology (109) 109
cardiovascular (109) 109
cells, cultured (109) 109
multiple sclerosis (109) 109
science & technology - other topics (109) 109
clinical trials (108) 108
diuretics (108) 108
anti-arrhythmia agents - adverse effects (106) 106
anti-arrhythmia agents - therapeutic use (105) 105
general & internal medicine (105) 105
multidisciplinary sciences (105) 105
drug dosages (103) 103
potassium channels - physiology (103) 103
calcium channels (102) 102
internal medicine (101) 101
cardiovascular disease (99) 99
cardiovascular diseases (98) 98
membrane potentials - drug effects (98) 98
mutation (95) 95
sodium (95) 95
double-blind method (94) 94
heart rate - drug effects (94) 94
medicine, general & internal (94) 94
torsades de pointes - chemically induced (94) 94
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2556) 2556
Japanese (22) 22
German (8) 8
Chinese (3) 3
Portuguese (3) 3
Russian (3) 3
French (2) 2
Danish (1) 1
Lithuanian (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Toxicological sciences, ISSN 1096-6080, 03/2017, Volume 156, Issue 1, pp. 25 - 38
.... Patient-specific iPSC-hCMs have been proposed for personalized cardiac drug selection and adverse drug response prediction... 
Drug-induced proarrhythmia | iPSC-CMs | Batch variations | Life Sciences & Biomedicine | Toxicology | Science & Technology | Arrhythmias, Cardiac - chemically induced | Drug Evaluation, Preclinical - economics | Calcium Channel Blockers - adverse effects | Anti-Arrhythmia Agents - pharmacology | Humans | Potassium Channel Blockers - antagonists & inhibitors | Toxicity Tests, Acute - methods | Potassium Channel Blockers - adverse effects | Arrhythmias, Cardiac - pathology | Shal Potassium Channels - genetics | Kv1.5 Potassium Channel - genetics | Toxicity Tests, Acute - economics | Induced Pluripotent Stem Cells - cytology | Voltage-Gated Sodium Channel Blockers - adverse effects | Potassium Channel Blockers - pharmacology | Induced Pluripotent Stem Cells - metabolism | Arrhythmias, Cardiac - metabolism | Induced Pluripotent Stem Cells - pathology | Cell Line | Drug Evaluation, Preclinical - methods | Reproducibility of Results | Induced Pluripotent Stem Cells - drug effects | Myocytes, Cardiac - cytology | Antioxidants - pharmacology | Calcium Channel Blockers - pharmacology | Gene Expression Regulation - drug effects | Myocytes, Cardiac - pathology | Shal Potassium Channels - metabolism | Calcium Channels, L-Type - genetics | Myocytes, Cardiac - drug effects | Cell Differentiation - drug effects | Kv1.5 Potassium Channel - metabolism | Calcium Channel Blockers - chemistry | Myocytes, Cardiac - metabolism | Voltage-Gated Sodium Channel Blockers - pharmacology | Calcium Channels, L-Type - metabolism | Kinetics | Electrophysiological Phenomena - drug effects | Index Medicus
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 09/2005, Volume 366, Issue 9489, pp. 895 - 906
The apparent shortfall in prevention of coronary heart disease (CHD) noted in early hypertension trials has been attributed to disadvantages of the diuretics and β blockers used... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Calcium Channel Blockers - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Bendroflumethiazide - administration & dosage | Hypertension - drug therapy | Male | Perindopril - administration & dosage | Sodium Chloride Symporter Inhibitors - administration & dosage | Diuretics | Adrenergic beta-Antagonists - adverse effects | Adult | Female | Blood Pressure - drug effects | Atenolol - administration & dosage | Drug Therapy, Combination | Amlodipine - administration & dosage | Adrenergic beta-Antagonists - administration & dosage | Risk Factors | Amlodipine - adverse effects | Angiotensin-Converting Enzyme Inhibitors - administration & dosage | Antihypertensive Agents - adverse effects | Coronary Disease - prevention & control | Calcium Channel Blockers - administration & dosage | Atenolol - adverse effects | Hypertension - complications | Aged | Hypertension | Antihypertensive drugs | Evaluation | Dosage and administration | Drug therapy | Prevention | Drug therapy, Combination | Health aspects | Coronary heart disease | Risk factors | Studies | Drugs | Cardiovascular disease | Medical treatment | Myocardial infarction | Heart attacks | Antihypertensives | Clinical trials | Family medical history | Evidence-based medicine | Blood | Randomization | Motivation | Blood pressure | Heart diseases | Antihypertensive agents | Cerebral infarction | Stroke | Fasting | Mortality | Diabetes mellitus | Health risks | Triglycerides | Metabolism | Risk analysis | Atenolol | Patients | Coronary artery disease | Cholesterol | Heart rate | Infarction | Diabetes | Cardiovascular diseases | Health risk assessment | Potassium | Index Medicus | Abridged Index Medicus | Amlodipine/administration & dosage/adverse effects | Bendroflumethiazide/administration & dosage | Cardiovascular Diseases/prevention & control | Perindopril/administration & dosage | MEDICIN OCH HÄLSOVETENSKAP | Atenolol/administration & dosage/adverse effects | Combination | Antihypertensive Agents/administration & dosage/adverse effects | Angiotensin-Converting Enzyme Inhibitors/administration & dosage | MEDICAL AND HEALTH SCIENCES | Coronary Disease/prevention & control | Drug Therapy | Adrenergic beta-Antagonists/administration & dosage/adverse effects | Blood Pressure/drug effects | Hypertension/complications/drug therapy | Calcium Channel Blockers/administration & dosage/adverse effects | Sodium Chloride Symporter Inhibitors/administration & dosage
Journal Article
Circulation (New York, N.Y.), ISSN 1524-4539, 10/2018, Volume 138, Issue 17, pp. 1879 - 1896
... approved and potential antiarrhythmic drugs on this centenary of his birth. RESULTS:We first consider the range of pharmacological targets, tracking these through to cellular electrophysiological effects... 
arrhythmias, cardiac | homeostasis | anti-arrhythmia agents | ion channels | Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Humans | Calcium Channel Blockers - therapeutic use | Potassium Channel Blockers - therapeutic use | Ion Channels - drug effects | Membrane Transport Modulators - classification | Arrhythmias, Cardiac - physiopathology | Heart Rate - drug effects | Voltage-Gated Sodium Channel Blockers - therapeutic use | Potassium Channel Blockers - classification | Action Potentials - drug effects | Arrhythmias, Cardiac - metabolism | Heart Conduction System - metabolism | Voltage-Gated Sodium Channel Blockers - classification | Terminology as Topic | Heart Conduction System - drug effects | Anti-Arrhythmia Agents - therapeutic use | Arrhythmias, Cardiac - drug therapy | Animals | Neurotransmitter Agents - therapeutic use | Anti-Arrhythmia Agents - classification | Heart Conduction System - physiopathology | Ion Channels - metabolism | Anti-Arrhythmia Agents - adverse effects | Membrane Transport Modulators - therapeutic use | Calcium Channel Blockers - classification | Arrhythmias, Cardiac - diagnosis | Neurotransmitter Agents - classification | Membrane Transport Modulators - adverse effects | Dosage and administration | Arrhythmia | Drug therapy | Anti-arrhythmia drugs | Index Medicus | Abridged Index Medicus
Journal Article
Current pharmaceutical design, ISSN 1381-6128, 06/2006, Volume 12, Issue 18, pp. 2271 - 2283
.... Moderate hERG blockade may produce a beneficial class III antiarrhythmic effect. In contrast, a reduction in hERG currents due to either genetic defects or adverse drug... 
Antiarrhythmic drugs | Short QT syndrome | Arrhythmia | Delayed rectifier potassium current | Long QT syndrome | Cardiac action potential | hERG potassium channel | Potassium - metabolism | Sympathetic Nervous System - drug effects | Humans | Ether-A-Go-Go Potassium Channels - metabolism | Potassium Channel Blockers - therapeutic use | ERG1 Potassium Channel | Potassium Channel Blockers - adverse effects | Sympathetic Nervous System - metabolism | Adrenergic beta-Antagonists - pharmacology | Receptors, Adrenergic - drug effects | Myocardium - metabolism | Stress, Physiological - metabolism | Potassium Channel Blockers - pharmacology | Adrenergic beta-Antagonists - therapeutic use | Heart - innervation | Arrhythmias, Cardiac - metabolism | Ether-A-Go-Go Potassium Channels - chemistry | Long QT Syndrome - etiology | Receptors, Adrenergic - metabolism | Models, Molecular | Anti-Arrhythmia Agents - therapeutic use | Ether-A-Go-Go Potassium Channels - genetics | Ether-A-Go-Go Potassium Channels - antagonists & inhibitors | Long QT Syndrome - metabolism | Arrhythmias, Cardiac - drug therapy | Animals | Anti-Arrhythmia Agents - adverse effects | Antidepressive Agents, Tricyclic - adverse effects | Heart - drug effects | Long QT Syndrome - genetics | Protein Conformation | Ion Channel Gating | Index Medicus
Journal Article
Cardiovascular research, ISSN 1755-3245, 07/2011, Volume 91, Issue 1, pp. 53 - 61
Journal Article